Invention Grant
- Patent Title: Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
-
Application No.: US14778046Application Date: 2014-03-19
-
Publication No.: US09957264B2Publication Date: 2018-05-01
- Inventor: Matthew Lloyd Childers , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Michelle Martinez , Danielle Falcone , Luis Torres , Yongqi Deng , Ravi Kurukulasuriya , Hongbo Zeng , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Patricia A. Shatynski; John C. Todaro
- Priority: WOPCT/CN2013/072873 20130319
- International Application: PCT/CN2014/000297 WO 20140319
- International Announcement: WO2014/146491 WO 20140925
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D519/00
Abstract:
The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
Public/Granted literature
- US20160272632A1 GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS Public/Granted day:2016-09-22
Information query
